Belt - BELT

iShares U.S. Select Equity Active ETF (NASDAQ: BELT)

Últimas noticias sobre iShares U.S. Select Equity Active ETF (NASDAQ:BELT)

The Fund invests at least 80% of its net assets, plus the amount of any borrowings for investment purposes, in equity securities of U.S. issuers and derivatives with similar economic characteristics. This policy is a non-fundamental policy of the Fund and may not be changed without 60 days prior notice to the Funds shareholders.

Microsoft Corp

Alphabet Holding Company Inc.

Meta Platforms, Inc.

Novo Nordisk A/S ADR

Mastercard Inc

S&P Global Inc

Cadence Design Systems Inc.

Trane Technologies Plc

Ingersoll-Rand Plc

Intuit, Inc.

BlackRock Long-Term US Equity ETF

Equities

Large Cap

News

BELT

iShares Trust Dow Jones US Financial Services Index Fund

Mastercard adquiere Recorded Future por $2.650M para mejorar sus servicios de ciberseguridad y prevenir amenazas en el ecosistema de pagos.

Mastercard comprará Recorded Future por $2650M para fortalecer su ciberseguridad

iShares U.S. Select Equity Active ETF

Belt Finance

<a href="https://www.bloomberg.com/news/articles/2025-07-29/trump-floats-skipping-g-20-summit-citing-rift-with-south-africa">https://www.bloomberg.com/news/articles/2025-07-29/trump-floats-skipping-g-20-summit-citing-rift-with-south-africa</a>

General

'Trump Floats Skipping G-20 Summit, Citing Rift With South Africa'- Bloomberg

WIIM

Sysco shares are trading lower after the company issued FY26 adjusted EPS guidance below estimates.

Reuters Cites U.S. Ambassador To Canada Saying "Hopefully Very Soon" A Trade Deal Between Canada And U.S. Will Be Reached

Crane shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 adjusted EPS guidance.

CHTR

Charter Communications shares are trading lower after UBS cut its price target on the stock from $425 to $355.

Centene shares are trading lower after JP Morgan cut its price target on the stock from $48 to $30.

Cemex shares are trading higher after Barclays raised its price target on the stock from $9 to $10.

<a href="https://www.cnbc.com/2025/07/29/nike-loses-head-of-north-america-womens-business-to-athleta.html">https://www.cnbc.com/2025/07/29/nike-loses-head-of-north-america-womens-business-to-athleta.html</a>

'Nike loses head of North America women's business to Athleta'- CNBC

Citigroup analyst Ygal Arounian maintains Teads Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAD#NASDAQ">TEAD</a>) with a Neutral and lowers the price target from $3.9 to $3.4.

Price Target

Analyst Ratings

TEAD

Citigroup Maintains Neutral on Teads Holding, Lowers Price Target to $3.4

Universal Health Services Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>), one of the largest healthcare management companies in the U.S., reported second-quarter adjusted earnings of $5.35 per share on Monday.
The company, which oversees hundreds of behavioral health facilities, beat <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">the consensus of $4.92</a>.
The King of Prussia, Pennsylvania-based hospital operator reported sales of $4.28 billion, up 9.6% year over year, beating the consensus estimate of $4.24 billion.
Also Read: <a href="https://www.benzinga.com/markets/earnings/25/07/46632096/hca-healthcare-eyes-76-billion-revenue-aggressive-profit-growth" target="_blank" rel="noreferrer noopener">HCA Healthcare Eyes $76 Billion Revenue, Aggressive Profit Growth</a>
<h2 class="wp-block-heading">Acute care hospitals</h2>
During the second quarter of 2025, at acute care hospitals owned during both periods (on the same facility basis), adjusted admissions (adjusted for outpatient activity) increased by 2.0%, while adjusted patient days <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/n46673559/universal-health-services-inc-announces-financial-results-for-the-three-and-six-month-periods-ende" rel="noreferrer noopener">increased by 1.1% year over year</a>.
Net revenue per adjusted admission increased by 3.8% while net revenue per adjusted patient day increased by 4.7%.
Net revenues generated from acute care services, on a same facility basis, increased by 7.9%.
<h2 class="wp-block-heading">Behavioral health care facilities</h2>
During the second quarter of 2025, at behavioral health care facilities on a same-facility basis, adjusted admissions increased by 0.4%, while adjusted patient days increased by 1.2%.
Net revenue per adjusted admission increased by 8.6% and net revenue per adjusted patient day increased by 7.8%.
Net revenues generated from behavioral health care services, on a same facility basis, increased by 8.9%.
Universal Health operates 29 inpatient acute care hospitals and 338 inpatient behavioral health facilities, plus 61 outpatient facilities.
<h2 class="wp-block-heading">Guidance</h2>
Universal Health Services raised fiscal year 2025 adjusted earnings from $18.45-$19.95&nbsp;per share to&nbsp;$20.00-$21.00, compared to the consensus of&nbsp;$19.68.
The company narrowed 2025 sales&nbsp;guidance&nbsp;from&nbsp;$17.02 billion-$17.36 billion to&nbsp;$17.09 billion-$17.31 billion, versus the consensus of&nbsp;$17.14 billion.
UHS revised its 2025 forecasted adjusted EBITDA to approximately&nbsp;$2.46 billion—$2.543 billion, compared to the prior range of $2.36 billion—$2.48 billion.
<h2 class="wp-block-heading">Analyst Take</h2>
Guggenheim Partners said adjusted EBITDA-NCI of $643 million beat the consensus estimate of $615 million. However, the company's underlying "core" performance was weaker than expected after removing $101 million in DPP payments not included in the original guidance and a $25 million added headwind from DC hospitals. The shortfall was mainly due to underperformance in the Behavioral segment.
Analyst Jason Cassorla writes, &#8220;However, we believe higher 2025 EBITDA and subsequently FCF likely translates into higher share repurchase, all-else equal, and that leverage at 1.9x gives the company ample flexibility to continue augmenting returns.&#8221;
Analyst Cassorla expects the stock to trade unevenly following the results, despite a ~15% drop in the past two weeks (compared to a 2% gain in the S&amp;P 500) and UHS trading at historically low valuation levels. Investors remain cautious about future growth in the behavioral health segment due to ongoing challenges in patient volumes.
Price Action: UHS stock is up 4.86% at $162.49&nbsp;at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46687002/ups-volume-takes-a-hit-on-tariff-induced-weakness-withholds-annual-outlook" target="_blank" rel="noreferrer noopener">UPS Volume Takes A Hit On Tariff-Induced Weakness, Withholds Annual Outlook</a></li>
</ul>
Image: Shutterstock

Analyst Color

Earnings

Guidance

Health Care

Movers

Trading Ideas

Behavioral Segment Concerns Overshadow Universal Health Q2 Earnings Beat

Citigroup analyst Jon Tower maintains Texas Roadhouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXRH#NASDAQ">TXRH</a>) with a Neutral and raises the price target from $180 to $197.

TXRH

Citigroup Maintains Neutral on Texas Roadhouse, Raises Price Target to $197

Citigroup analyst Yigal Nochomovitz maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Buy and raises the price target from $41 to $46.

APLS

Citigroup Maintains Buy on Apellis Pharmaceuticals, Raises Price Target to $46

APLS stock has given up its prior gain. Apellis Pharmaceuticals shares were trading higher after the company announced it has won FDA approval for EMPAVELI.

Citigroup analyst Peter Christiansen maintains Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) with a Buy and raises the price target from $270 to $505.

COIN

Citigroup Maintains Buy on Coinbase Global, Raises Price Target to $505

Macro Notification

Politics

Economics

Live On CNBC, U.S. Treasury's Bessent On China Trade Says Tik Tok Not Discussed; Taiwanese Movements Not Part Of Talks; In 90 Days Don't Know Where We're Going To Be;  Good News Is We're Talking; Now We Have Communications At All Levels

Tapestry, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>) stock declined Tuesday as analysts reassessed its valuation despite ongoing <a href="https://www.benzinga.com/quote/TPR/analyst-ratings" target="_blank" rel="noreferrer noopener">strength in the Coach brand</a>.
Bank of America Securities analyst Lorraine Hutchinson downgraded Tapestry from Buy to Hold on Tuesday, raising the price forecast from $95 to $115.
Hutchinson observes that while the Coach brand is set to deliver several more quarters of strong growth, the stock's 66% year-to-date rally, far outpacing the S&amp;P's 9%, has brought its valuation close to fair value.
Also Read: <a href="https://www.benzinga.com/markets/large-cap/25/07/46413056/tapestry-ups-investment-in-recycled-leather-pioneer-gen-phoenix" target="_blank" rel="noreferrer noopener">Coach Parent Tapestry Ups Investment In Recycled Leather Pioneer Gen Phoenix</a>
Over the past decade, Tapestry has traded at an average P/E of 13x, ranging between 6x and 20x, and is now sitting at the upper end of that range. As a result, she has moved to a Neutral stance, despite raising the price objective.
Hutchinson also anticipates a solid fourth quarter, forecasting EPS of 98 cents, matching management's guidance, and expects 5.4% sales growth and a 16.4% operating margin, while noting that a delayed Summer Sale may have boosted late-quarter sales, likely prompting an upbeat tone on the earnings call.
Hutchinson notes that fiscal year 2026 guidance will be closely watched, with expectations for mid-single-digit sales growth and stable margins, balancing tariff-related pressures with some SG&amp;A efficiency.
The analyst highlights that Coach continues to perform well, driven by successful marketing and premium product appeal, but doesn't foresee management forecasting double-digit growth for the brand this year.
While there's room for upside in fiscal year 2026 estimates, the analyst sees limited long-term margin expansion beyond Coach's already elevated 33.6% operating margin.
On tariffs, Hutchinson sees management can maintain profitability over time, though mitigation efforts will take a few quarters to ramp; the analyst projects a 60bp fiscal year 2026 gross margin decline from tariffs, with full recovery by fiscal year 2027, assuming initiatives scale and higher tariff rates accelerate those adjustments.
Price Action: TPR shares are trading lower by 2.35% to $107.83 at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/personal-finance/25/04/44656550/grant-cardone-roasts-luxury-items-and-recommends-real-estate-instead-birkin-bags-are-not-investments" target="_blank" rel="noreferrer noopener">Grant Cardone Roasts Luxury Items and Recommends Real Estate Instead: ‘Birkin Bags Are Not Investments'</a></li>
</ul>
Image via Shutterstock

Downgrades

Markets

Why Tapestry Stock Is Cooling Off Despite Coach's Hot Streak

Bausch Health Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHC#NYSE">BHC</a>) on Tuesday agreed to indirectly acquire DURECT Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>), including a novel <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">therapeutic molecule, larsucosterol</a>.
Larsucosterol, an endogenous sulfated oxysterol and an epigenetic modulator, has demonstrated promising results for alcoholic hepatitis (AH) in Phase 2 trials.
Alcoholic hepatitis is&nbsp;a severe liver inflammation caused by excessive alcohol consumption.&nbsp;It is characterized by the rapid onset of jaundice and liver enlargement.
Bausch Health&#8217;s hepatology development and commercial capabilities are well-suited to support the clinical development and potential commercialization of larsucosterol.
The companies add that there is currently no Food and Drug Administration- or European Medicines Agency-approved treatment for AH.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/05/45471704/icahn-ramps-up-bets-on-genes-and-jets-illumina-stake-jumps-450-jetblue-holding-grow-90" target="_blank" rel="noreferrer noopener">Icahn Ramps Up Bets On Genes And Jets: Illumina Stake Jumps 450%, JetBlue Holding Grow 90%</a>
Bausch Health will pay $1.75 per share in an all-cash transaction for an upfront consideration of approximately $63 million, with the potential for two additional net sales milestone payments of up to $350 million.
A registrational Phase 3 program to evaluate the safety and efficacy of larsucosterol for the treatment of patients with severe AH is being planned.
The trial will be a randomized, double-blind, placebo-controlled, multi-center study. The primary endpoint will be 90-day survival.
The trial design will incorporate feedback received from the FDA during a Type B meeting under Breakthrough Therapy Designation and learnings from the prior Phase 2b AHFIRM trial in AH.
The acquisition of the clinical development program for larsucosterol in AH complements the ongoing Bausch Health RED-C clinical program, which is designed to assess the efficacy of a next-generation therapeutic, rifaximin SSD, to delay the onset of first overt hepatic encephalopathy (OHE) hospitalization and all-cause mortality.
Patient enrollment in two global Phase 3 studies is now complete with efficacy and safety results expected to be announced in early 2026.
The transaction is expected to close in the third quarter of 2025.
Last year, Bausch Health <a href="https://www.benzinga.com/news/large-cap/24/10/41313679/bausch-lomb-sale-process-gains-momentum-as-tpg-and-blackstone-join-forces" target="_blank" rel="noreferrer noopener">was in talks with several</a> private equity firms about selling Bausch + Lomb Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NYSE">BLCO</a>).
The Bausch + Lomb spin-off was part of Bausch Health's plan to alleviate its $21 billion debt, a third&nbsp;<a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40884021/contact-lens-supplier-bausch-lomb-eyes-sale-amid-separation-challenges-as-parent-bausch-health-fac" rel="noreferrer noopener">of which is due by 2027</a>.
BHC, DRRX Price Actions: Bausch Health stock is down 0.36% at $6.87, and DURECT stock is up 238.34% at $1.87 at publication on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46688163/unitedhealth-misses-q2-mark-but-vows-a-healthier-2026" target="_blank" rel="noreferrer noopener">UnitedHealth Misses Q2 Mark But Vows A Healthier 2026</a></li>
</ul>
Photo: Shutterstock

Biotech

BLCO

DRRX

Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout

Rosenblatt analyst Kevin Cassidy maintains Rambus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBS#NASDAQ">RMBS</a>) with a Buy and raises the price target from $80 to $90.

RMBS

Rosenblatt Maintains Buy on Rambus, Raises Price Target to $90

Live On CNBC, U.S. Treasury's Bessent On Aug. 1 Trade Deadline Says Not End Of World If Tariffs Snap Back For Days Or Weeks As Long As Countries Trying To Negotiate; Happy To Do Deal Or Can Just Have Tariff Income

Live On CNBC, U.S. Treasury's Bessent On Vietnam Trade Says Assume We Have Confirmed Deal

Comments

iShares U.S. Select Equity Active ETF

Noticias

Últimas noticias sobre iShares U.S. Select Equity Active ETF (NASDAQ:BELT)

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL